Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Protein Phosphatase 1-Targeting Small-Molecule C31 Inhibits Ebola Virus Replication.

Ammosova T, Pietzsch CA, Saygideger Y, Ilatovsky A, Lin X, Ivanov A, Kumari N, Jerebtsova M, Kulkarni A, Petukhov M, Üren A, Bukreyev A, Nekhai S.

J Infect Dis. 2018 Aug 28. doi: 10.1093/infdis/jiy422. [Epub ahead of print]

PMID:
30169869
2.

Correction: Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Jan Pencik, Pham HTT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DNT, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2018 Jul 23;9(8):800. doi: 10.1038/s41419-018-0773-9.

3.

Investigating molecular interactions between oxidized neuroglobin and cytochrome c.

Tiwari PB, Chapagain PP, Üren A.

Sci Rep. 2018 Jul 12;8(1):10557. doi: 10.1038/s41598-018-28836-6.

4.

Subclonal mutation selection in mouse lymphomagenesis identifies known cancer loci and suggests novel candidates.

Webster P, Dawes JC, Dewchand H, Takacs K, Iadarola B, Bolt BJ, Caceres JJ, Kaczor J, Dharmalingam G, Dore M, Game L, Adejumo T, Elliott J, Naresh K, Karimi M, Rekopoulou K, Tan G, Paccanaro A, Uren AG.

Nat Commun. 2018 Jul 9;9(1):2649. doi: 10.1038/s41467-018-05069-9.

5.

Early synergistic interactions between the HPV16‑E7 oncoprotein and 17β-oestradiol for repressing the expression of Granzyme B in a cervical cancer model.

Munguía-Moreno JA, Díaz-Chavéz J, García-Villa E, Albino-Sanchez ME, Mendoza-Villanueva D, Ocadiz-Delgado R, Bonilla-Delgado J, Marín-Flores A, Cortés-Malagón EM, Alvarez-Rios E, Hidalgo-Miranda A, Üren A, Çelik H, Lambert PF, Gariglio P.

Int J Oncol. 2018 Aug;53(2):579-591. doi: 10.3892/ijo.2018.4432. Epub 2018 Jun 6.

6.

The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.

Fernandez HR, Gadre SM, Tan M, Graham GT, Mosaoa R, Ongkeko MS, Kim KA, Riggins RB, Parasido E, Petrini I, Pacini S, Cheema A, Varghese R, Ressom HW, Zhang Y, Albanese C, Üren A, Paige M, Giaccone G, Avantaggiati ML.

Cell Death Differ. 2018 Jul;25(7):1239-1258. doi: 10.1038/s41418-018-0101-z. Epub 2018 Apr 12.

7.

Clofarabine inhibits Ewing sarcoma growth through a novel molecular mechanism involving direct binding to CD99.

Çelik H, Sciandra M, Flashner B, Gelmez E, Kayraklıoğlu N, Allegakoen DV, Petro JR, Conn EJ, Hour S, Han J, Oktay L, Tiwari PB, Hayran M, Harris BT, Manara MC, Toretsky JA, Scotlandi K, Üren A.

Oncogene. 2018 Apr;37(16):2181-2196. doi: 10.1038/s41388-017-0080-4. Epub 2018 Jan 31.

PMID:
29382926
8.

Definition and symptoms of underactive bladder.

Uren AD, Drake MJ.

Investig Clin Urol. 2017 Dec;58(Suppl 2):S61-S67. doi: 10.4111/icu.2017.58.S2.S61. Epub 2017 Nov 13. Review.

9.

Inhibition of HIV-1 infection in humanized mice and metabolic stability of protein phosphatase-1-targeting small molecule 1E7-03.

Lin X, Kumari N, DeMarino C, Kont YS, Ammosova T, Kulkarni A, Jerebtsova M, Vazquez-Meves G, Ivanov A, Dmytro K, Üren A, Kashanchi F, Nekhai S.

Oncotarget. 2017 Aug 7;8(44):76749-76769. doi: 10.18632/oncotarget.19999. eCollection 2017 Sep 29.

10.

Inhibition of the oncogenic fusion protein EWS-FLI1 causes G2-M cell cycle arrest and enhanced vincristine sensitivity in Ewing's sarcoma.

Zöllner SK, Selvanathan SP, Graham GT, Commins RMT, Hong SH, Moseley E, Parks S, Haladyna JN, Erkizan HV, Dirksen U, Hogarty MD, Üren A, Toretsky JA.

Sci Signal. 2017 Oct 3;10(499). pii: eaam8429. doi: 10.1126/scisignal.aam8429.

PMID:
28974650
11.

Investigating cyclic nucleotide and cyclic dinucleotide binding to HCN channels by surface plasmon resonance.

Hayoz S, Tiwari PB, Piszczek G, Üren A, Brelidze TI.

PLoS One. 2017 Sep 26;12(9):e0185359. doi: 10.1371/journal.pone.0185359. eCollection 2017.

12.

Reply to Bora Lee and Jae Heon Kim's Letter to the Editor re: Alan D. Uren, Nikki Cotterill, Christopher Harding, et al. Qualitative Exploration of the Patient Experience of Underactive Bladder. Eur Urol 2017;72:402-7.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2018 Jan;73(1):e15-e16. doi: 10.1016/j.eururo.2017.07.037. Epub 2017 Aug 9. No abstract available.

PMID:
28801128
13.

Reply from Authors re: Mikkel Fode, Jens Sønksen. Towards a Greater Understanding of Underactive Bladder. Eur Urol 2017;72:408-9.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2017 Sep;72(3):409-410. doi: 10.1016/j.eururo.2017.06.039. Epub 2017 Jul 13. No abstract available.

PMID:
28712857
14.

Inhibition of ERG Activity in Patient-derived Prostate Cancer Xenografts by YK-4-279.

Winters B, Brown L, Coleman I, Nguyen H, Minas TZ, Kollath L, Vasioukhin V, Nelson P, Corey E, Üren A, Morrissey C.

Anticancer Res. 2017 Jul;37(7):3385-3396.

PMID:
28668826
15.

Qualitative Exploration of the Patient Experience of Underactive Bladder.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Klaver M, Bongaerts D, Hakimi Z, Abrams P.

Eur Urol. 2017 Sep;72(3):402-407. doi: 10.1016/j.eururo.2017.03.045. Epub 2017 Apr 8.

PMID:
28400168
16.

Visualizing Changes in Cdkn1c Expression Links Early-Life Adversity to Imprint Mis-regulation in Adults.

Van de Pette M, Abbas A, Feytout A, McNamara G, Bruno L, To WK, Dimond A, Sardini A, Webster Z, McGinty J, Paul EJ, Ungless MA, French PMW, Withers DJ, Uren A, Ferguson-Smith AC, Merkenschlager M, John RM, Fisher AG.

Cell Rep. 2017 Jan 31;18(5):1090-1099. doi: 10.1016/j.celrep.2017.01.010.

17.

An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease.

Carbo A, Gandour RD, Hontecillas R, Philipson N, Uren A, Bassaganya-Riera J.

J Med Chem. 2016 Nov 23;59(22):10113-10126. Epub 2016 Nov 15.

PMID:
27933891
18.

Increased survival and cell cycle progression pathways are required for EWS/FLI1-induced malignant transformation.

Javaheri T, Kazemi Z, Pencik J, Pham HT, Kauer M, Noorizadeh R, Sax B, Nivarthi H, Schlederer M, Maurer B, Hofbauer M, Aryee DN, Wiedner M, Tomazou EM, Logan M, Hartmann C, Tuckermann JP, Kenner L, Mikula M, Dolznig H, Üren A, Richter GH, Grebien F, Kovar H, Moriggl R.

Cell Death Dis. 2016 Oct 13;7(10):e2419. doi: 10.1038/cddis.2016.268. Erratum in: Cell Death Dis. 2018 Jul 23;9(8):800.

19.

Psychometric equivalence of electronic and telephone completion of the ICIQ modules.

Uren AD, Cotterill N, Parke SE, Abrams P.

Neurourol Urodyn. 2017 Jun;36(5):1342-1349. doi: 10.1002/nau.23103. Epub 2016 Aug 11.

PMID:
27513627
20.

Interaction Between HIV-1 Nef and Calnexin: From Modeling to Small Molecule Inhibitors Reversing HIV-Induced Lipid Accumulation.

Hunegnaw R, Vassylyeva M, Dubrovsky L, Pushkarsky T, Sviridov D, Anashkina AA, Üren A, Brichacek B, Vassylyev DG, Adzhubei AA, Bukrinsky M.

Arterioscler Thromb Vasc Biol. 2016 Sep;36(9):1758-71. doi: 10.1161/ATVBAHA.116.307997. Epub 2016 Jul 28.

21.

Characterization of molecular interactions between Escherichia coli RNA polymerase and topoisomerase I by molecular simulations.

Tiwari PB, Chapagain PP, Banda S, Darici Y, Üren A, Tse-Dinh YC.

FEBS Lett. 2016 Sep;590(17):2844-51. doi: 10.1002/1873-3468.12321. Epub 2016 Aug 4.

22.

Antimitotic activity of DY131 and the estrogen-related receptor beta 2 (ERRβ2) splice variant in breast cancer.

Heckler MM, Zeleke TZ, Divekar SD, Fernandez AI, Tiek DM, Woodrick J, Farzanegan A, Roy R, Üren A, Mueller SC, Riggins RB.

Oncotarget. 2016 Jul 26;7(30):47201-47220. doi: 10.18632/oncotarget.9719.

23.

Depletion of tyrosyl DNA phosphodiesterase 2 activity enhances etoposide-mediated double-strand break formation and cell killing.

Kont YS, Dutta A, Mallisetty A, Mathew J, Minas T, Kraus C, Dhopeshwarkar P, Kallakury B, Mitra S, Üren A, Adhikari S.

DNA Repair (Amst). 2016 Jul;43:38-47. doi: 10.1016/j.dnarep.2016.04.009. Epub 2016 May 7.

PMID:
27235629
24.

Combined experience of six independent laboratories attempting to create an Ewing sarcoma mouse model.

Minas TZ, Surdez D, Javaheri T, Tanaka M, Howarth M, Kang HJ, Han J, Han ZY, Sax B, Kream BE, Hong SH, Çelik H, Tirode F, Tuckermann J, Toretsky JA, Kenner L, Kovar H, Lee S, Sweet-Cordero EA, Nakamura T, Moriggl R, Delattre O, Üren A.

Oncotarget. 2017 May 23;8(21):34141-34163. doi: 10.18632/oncotarget.9388.

25.

Ezrin Inhibition Up-regulates Stress Response Gene Expression.

Çelik H, Bulut G, Han J, Graham GT, Minas TZ, Conn EJ, Hong SH, Pauly GT, Hayran M, Li X, Özdemirli M, Ayhan A, Rudek MA, Toretsky JA, Üren A.

J Biol Chem. 2016 Jun 17;291(25):13257-70. doi: 10.1074/jbc.M116.718189. Epub 2016 May 2.

26.

Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.

Roudier MP, Winters BR, Coleman I, Lam HM, Zhang X, Coleman R, Chéry L, True LD, Higano CS, Montgomery B, Lange PH, Snyder LA, Srivastava S, Corey E, Vessella RL, Nelson PS, Üren A, Morrissey C.

Prostate. 2016 Jun;76(9):810-22. doi: 10.1002/pros.23171. Epub 2016 Mar 16.

27.

Ezrin Enhances EGFR Signaling and Modulates Erlotinib Sensitivity in Non-Small Cell Lung Cancer Cells.

Saygideğer-Kont Y, Minas TZ, Jones H, Hour S, Çelik H, Temel I, Han J, Atabey N, Erkizan HV, Toretsky JA, Üren A.

Neoplasia. 2016 Feb;18(2):111-20. doi: 10.1016/j.neo.2016.01.002.

28.

Identification of a binding site of the human immunodeficiency virus envelope protein gp120 to neuronal-specific tubulin.

Avdoshina V, Taraballi F, Dedoni S, Corbo C, Paige M, Saygideğer Kont Y, Üren A, Tasciotti E, Mocchetti I.

J Neurochem. 2016 Apr;137(2):287-98. doi: 10.1111/jnc.13557. Epub 2016 Mar 15.

29.

The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease.

Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O.

Oncotarget. 2016 Feb 23;7(8):8613-24. doi: 10.18632/oncotarget.6937. Review.

30.

Modeling-Enabled Characterization of Novel NLRX1 Ligands.

Lu P, Hontecillas R, Abedi V, Kale S, Leber A, Heltzel C, Langowski M, Godfrey V, Philipson C, Tubau-Juni N, Carbo A, Girardin S, Uren A, Bassaganya-Riera J.

PLoS One. 2015 Dec 29;10(12):e0145420. doi: 10.1371/journal.pone.0145420. eCollection 2015.

31.

Note: Model identification and analysis of bivalent analyte surface plasmon resonance data.

Tiwari PB, Üren A, He J, Darici Y, Wang X.

Rev Sci Instrum. 2015 Oct;86(10):106107. doi: 10.1063/1.4933318.

32.

YK-4-279 effectively antagonizes EWS-FLI1 induced leukemia in a transgenic mouse model.

Minas TZ, Han J, Javaheri T, Hong SH, Schlederer M, Saygideğer-Kont Y, Çelik H, Mueller KM, Temel I, Özdemirli M, Kovar H, Erkizan HV, Toretsky J, Kenner L, Moriggl R, Üren A.

Oncotarget. 2015 Nov 10;6(35):37678-94. doi: 10.18632/oncotarget.5520.

33.

Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box.

Çelik H, Hong SH, Colón-López DD, Han J, Kont YS, Minas TZ, Swift M, Paige M, Glasgow E, Toretsky JA, Bosch J, Üren A.

Mol Cancer Ther. 2015 Nov;14(11):2497-507. doi: 10.1158/1535-7163.MCT-15-0511. Epub 2015 Sep 10.

34.

Dual EZH2 and EHMT2 histone methyltransferase inhibition increases biological efficacy in breast cancer cells.

Curry E, Green I, Chapman-Rothe N, Shamsaei E, Kandil S, Cherblanc FL, Payne L, Bell E, Ganesh T, Srimongkolpithak N, Caron J, Li F, Uren AG, Snyder JP, Vedadi M, Fuchter MJ, Brown R.

Clin Epigenetics. 2015 Aug 21;7:84. doi: 10.1186/s13148-015-0118-9. eCollection 2015.

35.

Reactivation of latent HIV-1 provirus via targeting protein phosphatase-1.

Tyagi M, Iordanskiy S, Ammosova T, Kumari N, Smith K, Breuer D, Ilatovskiy AV, Kont YS, Ivanov A, Üren A, Kovalskyy D, Petukhov M, Kashanchi F, Nekhai S.

Retrovirology. 2015 Jul 16;12:63. doi: 10.1186/s12977-015-0190-4.

36.

Human papillomavirus type 16 E7 oncoprotein upregulates the retinoic acid receptor-beta expression in cervical cancer cell lines and K14E7 transgenic mice.

Gutiérrez J, García-Villa E, Ocadiz-Delgado R, Cortés-Malagón EM, Vázquez J, Roman-Rosales A, Alvarez-Rios E, Celik H, Romano MC, Üren A, Lambert PF, Gariglio P.

Mol Cell Biochem. 2015 Oct;408(1-2):261-72. doi: 10.1007/s11010-015-2504-1. Epub 2015 Jul 15.

PMID:
26173416
37.

Ezrin Binds to DEAD-Box RNA Helicase DDX3 and Regulates Its Function and Protein Level.

Çelik H, Sajwan KP, Selvanathan SP, Marsh BJ, Pai AV, Kont YS, Han J, Minas TZ, Rahim S, Erkizan HV, Toretsky JA, Üren A.

Mol Cell Biol. 2015 Sep;35(18):3145-62. doi: 10.1128/MCB.00332-15. Epub 2015 Jul 6.

38.

Inorganic polyphosphates are important for cell survival and motility of human skin keratinocytes.

Simbulan-Rosenthal CM, Gaur A, Sanabria VA, Dussan LJ, Saxena R, Schmidt J, Kitani T, Chen YS, Rahim S, Uren A, Crooke E, Rosenthal DS.

Exp Dermatol. 2015 Aug;24(8):636-9. doi: 10.1111/exd.12729. Epub 2015 May 8. No abstract available.

PMID:
25869331
39.

Oncogenic fusion protein EWS-FLI1 is a network hub that regulates alternative splicing.

Selvanathan SP, Graham GT, Erkizan HV, Dirksen U, Natarajan TG, Dakic A, Yu S, Liu X, Paulsen MT, Ljungman ME, Wu CH, Lawlor ER, Üren A, Toretsky JA.

Proc Natl Acad Sci U S A. 2015 Mar 17;112(11):E1307-16. doi: 10.1073/pnas.1500536112. Epub 2015 Mar 3.

40.

RNA helicase A activity is inhibited by oncogenic transcription factor EWS-FLI1.

Erkizan HV, Schneider JA, Sajwan K, Graham GT, Griffin B, Chasovskikh S, Youbi SE, Kallarakal A, Chruszcz M, Padmanabhan R, Casey JL, Üren A, Toretsky JA.

Nucleic Acids Res. 2015 Jan;43(2):1069-80. doi: 10.1093/nar/gku1328. Epub 2015 Jan 6.

41.

Germ line variants of human N-methylpurine DNA glycosylase show impaired DNA repair activity and facilitate 1,N6-ethenoadenine-induced mutations.

Adhikari S, Chetram MA, Woodrick J, Mitra PS, Manthena PV, Khatkar P, Dakshanamurthy S, Dixon M, Karmahapatra SK, Nuthalapati NK, Gupta S, Narasimhan G, Mazumder R, Loffredo CA, Üren A, Roy R.

J Biol Chem. 2015 Feb 20;290(8):4966-80. doi: 10.1074/jbc.M114.627000. Epub 2014 Dec 23.

42.

A small molecule inhibitor of ETV1, YK-4-279, prevents prostate cancer growth and metastasis in a mouse xenograft model.

Rahim S, Minas T, Hong SH, Justvig S, Çelik H, Kont YS, Han J, Kallarakal AT, Kong Y, Rudek MA, Brown ML, Kallakury B, Toretsky JA, Üren A.

PLoS One. 2014 Dec 5;9(12):e114260. doi: 10.1371/journal.pone.0114260. eCollection 2014.

43.

Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.

Tosso PN, Kong Y, Scher L, Cummins R, Schneider J, Rahim S, Holman KT, Toretsky J, Wang K, Üren A, Brown ML.

J Med Chem. 2014 Dec 26;57(24):10290-303. doi: 10.1021/jm501372p. Epub 2014 Dec 12.

44.

Generation of K14-E7/∆N87βcat double transgenic mice as a model of cervical cancer.

Bulut G, Üren A.

Methods Mol Biol. 2015;1249:393-406. doi: 10.1007/978-1-4939-2013-6_29.

PMID:
25348322
45.

The experiences of male sudden cardiac arrest survivors and their partners: a gender analysis.

Uren A, Galdas P.

J Adv Nurs. 2015 Feb;71(2):349-58. doi: 10.1111/jan.12499. Epub 2014 Aug 4.

PMID:
25092134
46.

1E7-03, a low MW compound targeting host protein phosphatase-1, inhibits HIV-1 transcription.

Ammosova T, Platonov M, Ivanov A, Kont YS, Kumari N, Kehn-Hall K, Jerebtsova M, Kulkarni AA, Uren A, Kovalskyy D, Nekhai S.

Br J Pharmacol. 2014 Nov;171(22):5059-75. doi: 10.1111/bph.12863.

47.

Effect of oven cooking method on formation of heterocyclic amines and quality characteristics of chicken patties: steam-assisted hybrid oven versus convection ovens.

Isleroglu H, Kemerli T, Özdestan Ö, Uren A, Kaymak-Ertekin F.

Poult Sci. 2014 Sep;93(9):2296-303. doi: 10.3382/ps.2013-03552. Epub 2014 Jun 28.

PMID:
24974393
48.

Toward a drug development path that targets metastatic progression in osteosarcoma.

Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS, Merlino G, Sorensen PH, Meltzer P, Kirsch DG, Janeway KA, Weigel B, Randall L, Withrow SJ, Paoloni M, Kaplan R, Teicher BA, Seibel NL, Smith M, Uren A, Patel SR, Trent J, Savage SA, Mirabello L, Reinke D, Barkaukas DA, Krailo M, Bernstein M.

Clin Cancer Res. 2014 Aug 15;20(16):4200-9. doi: 10.1158/1078-0432.CCR-13-2574. Epub 2014 May 6.

49.

Cadherin-11 in poor prognosis malignancies and rheumatoid arthritis: common target, common therapies.

Assefnia S, Dakshanamurthy S, Guidry Auvil JM, Hampel C, Anastasiadis PZ, Kallakury B, Uren A, Foley DW, Brown ML, Shapiro L, Brenner M, Haigh D, Byers SW.

Oncotarget. 2014 Mar 30;5(6):1458-74.

50.

Pharmacokinetic modeling optimizes inhibition of the 'undruggable' EWS-FLI1 transcription factor in Ewing Sarcoma.

Hong SH, Youbi SE, Hong SP, Kallakury B, Monroe P, Erkizan HV, Barber-Rotenberg JS, Houghton P, Üren A, Toretsky JA.

Oncotarget. 2014 Jan 30;5(2):338-50.

Supplemental Content

Support Center